These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 27493187)

  • 21. Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.
    Gallastegui N; Groll M
    Methods Mol Biol; 2012; 832():373-90. PubMed ID: 22350899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular characterization of the boron adducts of the proteasome inhibitor bortezomib with epigallocatechin-3-gallate and related polyphenols.
    Glynn SJ; Gaffney KJ; Sainz MA; Louie SG; Petasis NA
    Org Biomol Chem; 2015 Apr; 13(13):3887-99. PubMed ID: 25669488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design of proteasome inhibitors with oral efficacy in vivo against
    Xie SC; Metcalfe RD; Mizutani H; Puhalovich T; Hanssen E; Morton CJ; Du Y; Dogovski C; Huang SC; Ciavarri J; Hales P; Griffin RJ; Cohen LH; Chuang BC; Wittlin S; Deni I; Yeo T; Ward KE; Barry DC; Liu B; Gillett DL; Crespo-Fernandez BF; Ottilie S; Mittal N; Churchyard A; Ferguson D; Aguiar ACC; Guido RVC; Baum J; Hanson KK; Winzeler EA; Gamo FJ; Fidock DA; Baud D; Parker MW; Brand S; Dick LR; Griffin MDW; Gould AE; Tilley L
    Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34548400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of novel 20S proteasome inhibitors by rational topology-based scaffold hopping of bortezomib.
    Xu Y; Yang X; Chen Y; Chen H; Sun H; Li W; Xie Q; Yu L; Shao L
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2148-2152. PubMed ID: 29773504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer.
    Yerlikaya A; Kanbur E; Stanley BA; Tümer E
    Anticancer Agents Med Chem; 2021; 21(1):20-32. PubMed ID: 32781973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Merging the Versatile Functionalities of Boronic Acid with Peptides.
    Tan Y; Wu J; Song L; Zhang M; Hipolito CJ; Wu C; Wang S; Zhang Y; Yin Y
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome.
    Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M
    J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
    Kupperman E; Lee EC; Cao Y; Bannerman B; Fitzgerald M; Berger A; Yu J; Yang Y; Hales P; Bruzzese F; Liu J; Blank J; Garcia K; Tsu C; Dick L; Fleming P; Yu L; Manfredi M; Rolfe M; Bolen J
    Cancer Res; 2010 Mar; 70(5):1970-80. PubMed ID: 20160034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome.
    Hasinoff BB
    Arch Biochem Biophys; 2018 Feb; 639():52-58. PubMed ID: 29305052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
    Piva R; Ruggeri B; Williams M; Costa G; Tamagno I; Ferrero D; Giai V; Coscia M; Peola S; Massaia M; Pezzoni G; Allievi C; Pescalli N; Cassin M; di Giovine S; Nicoli P; de Feudis P; Strepponi I; Roato I; Ferracini R; Bussolati B; Camussi G; Jones-Bolin S; Hunter K; Zhao H; Neri A; Palumbo A; Berkers C; Ovaa H; Bernareggi A; Inghirami G
    Blood; 2008 Mar; 111(5):2765-75. PubMed ID: 18057228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914.
    Huber EM; Heinemeyer W; Groll M
    Structure; 2015 Feb; 23(2):407-17. PubMed ID: 25599643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-resolution cryo-EM proteasome structures in drug development.
    Morris EP; da Fonseca PCA
    Acta Crystallogr D Struct Biol; 2017 Jun; 73(Pt 6):522-533. PubMed ID: 28580914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of peptidomimetic boronates as proteasome inhibitors.
    Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M
    Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Updated Review and Perspective on 20S Proteasome Inhibitors in the Treatment of Lung Cancer.
    Rohondia SO; Ahmed ZSO; Dou QP
    Curr Cancer Drug Targets; 2020; 20(6):392-409. PubMed ID: 32101123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
    Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
    Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure- and function-based design of Plasmodium-selective proteasome inhibitors.
    Li H; O'Donoghue AJ; van der Linden WA; Xie SC; Yoo E; Foe IT; Tilley L; Craik CS; da Fonseca PC; Bogyo M
    Nature; 2016 Feb; 530(7589):233-6. PubMed ID: 26863983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Proteasome inhibitors in cancer therapy].
    Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
    Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview.
    Guedes RA; Serra P; Salvador JA; Guedes RC
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urea-containing peptide boronic acids as potent proteasome inhibitors.
    Han LQ; Yuan X; Wu XY; Li RD; Xu B; Cheng Q; Liu ZM; Zhou TY; An HY; Wang X; Cheng TM; Ge ZM; Cui JR; Li RT
    Eur J Med Chem; 2017 Jan; 125():925-939. PubMed ID: 27769033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.